Newsletter Tool

To view this email as a web page, click here

Today's Rundown

It's official: Pfizer, BioNTech ink enormous deal with Europe to provide 1.8B more COVID-19 vaccine doses
RenBio joins bigwigs Eli Lilly, Regeneron in hunt for next gen COVID-19 antibodies after $24M financing
What Amazon's potential move into at-home medical tests could mean for the market
Emergent was unequipped to produce both J&J and AstraZeneca COVID-19 vaccines, execs tell lawmakers
COVID-19 tracker: India's Bharat Biotech boosts vaccine production; Japan set to approve Moderna, AZ jabs
HCA Healthcare CFO outlines M&A growth strategy, post-COVID hurdles facing the health system
The Wheel deal: Virtual care startup rolls into $50M series B to grow telehealth software, clinician network
CHS reports strong rebound in lower-acuity procedures compared to higher-acuity surgeries

Featured Story

It's official: Pfizer, BioNTech ink enormous deal with Europe to provide 1.8B more COVID-19 vaccine doses

By Kevin Dunleavy

A much-discussed COVID-19 vaccine supply deal between Pfizer, BioNTech and Europe is now official. The companies said they will supply 1.8 billion doses of the shot through 2023, bringing their total supply to the bloc at 2.4 billion.

RenBio joins bigwigs Eli Lilly, Regeneron in hunt for next gen COVID-19 antibodies after $24M financing

By Kyle LaHucik

A year and a half ago, the disease targeted by RenBio's lead asset did not even exist in humans, but now the upstart biotech is emerging from stealth with a COVID-19 antibody hopeful and $24 million in financing to go up against Big Pharma in the battle for a variant-busting treatment.

What Amazon's potential move into at-home medical tests could mean for the market

By Heather Landi

Amazon is considering the launch of a new line of business that offers at-home medical tests, according to media reports. It's a potential move that wouldn't surprise many industry analysts. "Labs are a particularly good fit for the core strengths of Amazon," said consultant Nathan Ray. Here's how Amazon's next healthcare move could impact the market.

Emergent was unequipped to produce both J&J and AstraZeneca COVID-19 vaccines, execs tell lawmakers

By Fraiser Kansteiner

Emergent BioSolutions execs said the "unprecedented" challenge of scaling up production for both AstraZeneca and Johnson & Johnson's COVID-19 vaccines caused its pandemic manufacturing struggles.

COVID-19 tracker: India's Bharat Biotech boosts vaccine production; Japan set to approve Moderna, AZ jabs

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

India's Bharat Biotech said it will now be able to produce 200 million additional doses of its vaccine, known as Covaxin, per year. A key Japanese health panel endorsed the shots from AstraZeneca and Moderna, setting them up for full government approval as early as Friday. And more headlines.

HCA Healthcare CFO outlines M&A growth strategy, post-COVID hurdles facing the health system

By Dave Muoio

Growth is front of mind for the large for-profit system, particularly when it comes to in-market opportunities around continuing services. At the same time, CFO Bill Rutherford said HCA and others will likely feel the lingering impacts of disrupted utilization and workforce burnout for months to come.

The Wheel deal: Virtual care startup rolls into $50M series B to grow telehealth software, clinician network

By Andrea Park

With nearly $70 million in lifetime venture funding under its belt, Wheel isn’t looking to reinvent its eponymous device—just the entire telehealth industry.

CHS reports strong rebound in lower-acuity procedures compared to higher-acuity surgeries

By Robert King

Community Health System executives said lower-acuity services and procedures like diagnostics and screenings have seen a stronger rebound compared to more complex and higher-acuity surgeries.

COVID-19 Tracker